<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1-3.dtd?>
<?SourceDTD.Version 1.3?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Molecules</journal-id>
    <journal-id journal-id-type="iso-abbrev">Molecules</journal-id>
    <journal-id journal-id-type="publisher-id">molecules</journal-id>
    <journal-title-group>
      <journal-title>Molecules</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1420-3049</issn>
    <publisher>
      <publisher-name>MDPI</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9227411</article-id>
    <article-id pub-id-type="doi">10.3390/molecules27123931</article-id>
    <article-id pub-id-type="publisher-id">molecules-27-03931</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>AddictedChem: A Data-Driven Integrated Platform for New Psychoactive Substance Identification</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5473-3432</contrib-id>
        <name>
          <surname>Han</surname>
          <given-names>Mengying</given-names>
        </name>
        <xref rid="af1-molecules-27-03931" ref-type="aff">1</xref>
        <xref rid="fn1-molecules-27-03931" ref-type="author-notes">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2923-3356</contrib-id>
        <name>
          <surname>Liu</surname>
          <given-names>Sheng</given-names>
        </name>
        <xref rid="af1-molecules-27-03931" ref-type="aff">1</xref>
        <xref rid="fn1-molecules-27-03931" ref-type="author-notes">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2467-6286</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Dachuan</given-names>
        </name>
        <xref rid="af1-molecules-27-03931" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Rui</given-names>
        </name>
        <xref rid="af1-molecules-27-03931" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Dongliang</given-names>
        </name>
        <xref rid="af1-molecules-27-03931" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Xing</surname>
          <given-names>Huadong</given-names>
        </name>
        <xref rid="af1-molecules-27-03931" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sun</surname>
          <given-names>Dandan</given-names>
        </name>
        <xref rid="af1-molecules-27-03931" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gong</surname>
          <given-names>Linlin</given-names>
        </name>
        <xref rid="af1-molecules-27-03931" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7910-6558</contrib-id>
        <name>
          <surname>Cai</surname>
          <given-names>Pengli</given-names>
        </name>
        <xref rid="af1-molecules-27-03931" ref-type="aff">1</xref>
        <xref rid="af2-molecules-27-03931" ref-type="aff">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tu</surname>
          <given-names>Weizhong</given-names>
        </name>
        <xref rid="af3-molecules-27-03931" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Junni</given-names>
        </name>
        <xref rid="af3-molecules-27-03931" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hu</surname>
          <given-names>Qian-Nan</given-names>
        </name>
        <xref rid="af1-molecules-27-03931" ref-type="aff">1</xref>
        <xref rid="c1-molecules-27-03931" ref-type="corresp">*</xref>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Kireev</surname>
          <given-names>Dmitri B.</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
      <contrib contrib-type="editor">
        <name>
          <surname>Tsigelny</surname>
          <given-names>Igor F.</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <aff id="af1-molecules-27-03931"><label>1</label>CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China; <email>hanmengying2018@sibs.ac.cn</email> (M.H.); <email>liusheng2019@sibs.ac.cn</email> (S.L.); <email>zhangdachuan2017@sibs.ac.cn</email> (D.Z.); <email>zhangrui2019@sibs.ac.cn</email> (R.Z.); <email>liudongliang2018@sibs.ac.cn</email> (D.L.); <email>xinghuadong2019@sibs.ac.cn</email> (H.X.); <email>sundandan2017@sibs.ac.cn</email> (D.S.); <email>gonglinlin2018@sibs.ac.cn</email> (L.G.); <email>caipengli@picb.ac.cn</email> (P.C.)</aff>
    <aff id="af2-molecules-27-03931"><label>2</label>Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China</aff>
    <aff id="af3-molecules-27-03931"><label>3</label>Wuhan LifeSynther Science and Technology Co., Limited, Wuhan 430000, China; <email>tuweizhong@163.com</email> (W.T.); <email>service@esynbio.com</email> (J.C.)</aff>
    <author-notes>
      <corresp id="c1-molecules-27-03931"><label>*</label>Correspondence: <email>qnhu@sibs.ac.cn</email>; Tel.: +86-021-54920615</corresp>
      <fn id="fn1-molecules-27-03931">
        <label>†</label>
        <p>These authors contributed equally to this work.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>19</day>
      <month>6</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <month>6</month>
      <year>2022</year>
    </pub-date>
    <volume>27</volume>
    <issue>12</issue>
    <elocation-id>3931</elocation-id>
    <history>
      <date date-type="received">
        <day>19</day>
        <month>2</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>14</day>
        <month>6</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2022 by the authors.</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p>The mechanisms underlying drug addiction remain nebulous. Furthermore, new psychoactive substances (NPS) are being developed to circumvent legal control; hence, rapid NPS identification is urgently needed. Here, we present the construction of the comprehensive database of controlled substances, AddictedChem. This database integrates the following information on controlled substances from the US Drug Enforcement Administration: physical and chemical characteristics; classified literature by Medical Subject Headings terms and target binding data; absorption, distribution, metabolism, excretion, and toxicity; and related genes, pathways, and bioassays. We created 29 predictive models for NPS identification using five machine learning algorithms and seven molecular descriptors. The best performing models achieved a balanced accuracy (BA) of 0.940 with an area under the curve (AUC) of 0.986 for the test set and a BA of 0.919 and an AUC of 0.968 for the external validation set, which were subsequently used to identify potential NPS with a consensus strategy. Concurrently, a chemical space that included the properties of vectorised addictive compounds was constructed and integrated with AddictedChem, illustrating the principle of diversely existing NPS from a macro perspective. Based on these potential applications, AddictedChem could be considered a highly promising tool for NPS identification and evaluation.</p>
    </abstract>
    <kwd-group>
      <kwd>drug addiction</kwd>
      <kwd>database</kwd>
      <kwd>new psychoactive substance</kwd>
      <kwd>machine learning</kwd>
      <kwd>prediction</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>National Key Research and Development Program of China</funding-source>
        <award-id>2020YFA0908300</award-id>
        <award-id>2019YFA0904300</award-id>
        <award-id>2018YFA0900700</award-id>
      </award-group>
      <award-group>
        <funding-source>CAS International Partnership Programme of the Chinese Academy of Sciences of China</funding-source>
        <award-id>153D31KYSB20170121</award-id>
      </award-group>
      <funding-statement>This work was supported by the National Key Research and Development Program of China (grant numbers: 2020YFA0908300, 2019YFA0904300, 2018YFA0900700) and the CAS International Partnership Programme of the Chinese Academy of Sciences of China (grant number 153D31KYSB20170121).</funding-statement>
    </funding-group>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="sec1-molecules-27-03931">
    <title>1. Introduction</title>
    <p>Drug addiction is a chronic relapsing disease that involves drug sourcing and continuous use and adversely affects the brain. Individuals with drug addiction represent all age groups. Drug addiction often causes serious physical and mental damage to the individual, leading to societal problems, such as rising social crime rates and economic losses. The 2021 World Drug Report of the United Nations Office on Drugs and Crime (UNODC) indicated that approximately 275 million people took drugs worldwide in 2020, whereas more than 36 million individuals had drug use disorders [<xref rid="B1-molecules-27-03931" ref-type="bibr">1</xref>]. Consequently, specific regulations have been introduced to control addictive compounds. The United Nations formulated three United Nations conventions in 1961 [<xref rid="B2-molecules-27-03931" ref-type="bibr">2</xref>], 1971 [<xref rid="B3-molecules-27-03931" ref-type="bibr">3</xref>], and 1988 [<xref rid="B4-molecules-27-03931" ref-type="bibr">4</xref>] to classify addicted drugs and precursors. The European Union has no legislation to classify narcotic or psychotropic substances, while it has a pan-European control for rapid detection. For the USA, the Controlled Substances Act is a statute of the US Drug Enforcement Administration (DEA), which establishes federal US drug policy under which the manufacture, importation, possession, use, and distribution of certain substances is regulated [<xref rid="B5-molecules-27-03931" ref-type="bibr">5</xref>]. Depending on the risk of dependence and abuse, and addiction likelihood, controlled substances are divided into Schedule I–V levels, where level I comprises research drugs whose use for medical purposes is strictly prohibited, and drugs in the other four categories can be used for medical treatment.</p>
    <p>Most controlled compounds are agonists of receptors of the human central nervous system, such as opioid receptors, cannabis receptors, 5-hydroxytryptamine receptors, acetylcholine receptors, dopamine receptors, and γ-aminobutyric acid receptors [<xref rid="B6-molecules-27-03931" ref-type="bibr">6</xref>]. The specific addiction mechanism may be related to the reward circuit mechanism in the brain [<xref rid="B7-molecules-27-03931" ref-type="bibr">7</xref>]. For example, morphine stimulates μ receptors located on γ-aminobutyric acid neurons in the ventral tegmental area (VTA), thus disinhibiting dopaminergic neurons. This effect consequently promotes dopamine release from the VTA to the nucleus accumbens, triggering a rewarding effect [<xref rid="B8-molecules-27-03931" ref-type="bibr">8</xref>,<xref rid="B9-molecules-27-03931" ref-type="bibr">9</xref>]. However, the specific mechanism of addiction to most controlled substances remains unclear [<xref rid="B10-molecules-27-03931" ref-type="bibr">10</xref>], and different levels of information must be integrated for in-depth research into controlled substances. However, a large amount of experimental data on controlled compounds exists in the scientific literature and databases. For example, the DrugBank database [<xref rid="B11-molecules-27-03931" ref-type="bibr">11</xref>] contains information on the physiological targets and pharmacological effects of some controlled compounds; admetSAR [<xref rid="B12-molecules-27-03931" ref-type="bibr">12</xref>] contains experimental and predicted values of the absorption, distribution, metabolism, excretion, and toxicity (ADMET) of controlled compounds; BindingDB [<xref rid="B13-molecules-27-03931" ref-type="bibr">13</xref>] provides comprehensive information about protein–target interactions related to controlled compounds; and the Comparative Toxicogenomics Database (CTD) [<xref rid="B14-molecules-27-03931" ref-type="bibr">14</xref>] provides detailed information on the interaction of controlled substances with genes and molecular pathways. To date, no single database provides experimental biologists with comprehensive information on controlled substances.</p>
    <p>In addition to controlled substances <italic toggle="yes">per se</italic>, their analogues, i.e., new psychoactive substances (NPS), are constantly devised [<xref rid="B15-molecules-27-03931" ref-type="bibr">15</xref>]. NPS are molecules that exert strong psychoactive effects mimicking the effects of legal recreational drugs and are difficult to detect by routine drug screening [<xref rid="B16-molecules-27-03931" ref-type="bibr">16</xref>]. The UNODC first used the term ‘new psychoactive substances’ to refer to ‘substances of abuse, either in a pure form or as a preparation, that are not controlled by the 1961 Single Convention on Narcotic Drugs or the 1971 Convention on Psychotropic Substances, but which may pose a public health threat’ [<xref rid="B17-molecules-27-03931" ref-type="bibr">17</xref>]. For example, a synthetic stimulant called ‘bath salt’ is a cathinone analogue [<xref rid="B18-molecules-27-03931" ref-type="bibr">18</xref>]. At the end of 2020, approximately 830 NPS were monitored by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and their numbers continue to increase [<xref rid="B15-molecules-27-03931" ref-type="bibr">15</xref>]. How to classify NPS from the many substances is an important issue that is challenging. Within drug samples, forensic and toxicological analyses can detect, identify, and quantify NPS. However, without a certified sample, NPS can be screened using methods such as high-resolution mass spectrometry [<xref rid="B19-molecules-27-03931" ref-type="bibr">19</xref>]. The above efforts to identify and predict NPS are cost- and time-consuming. From a computational viewpoint, a quantitative structure–activity relationship model was used to verify the analogues of amphetamine cathinone [<xref rid="B20-molecules-27-03931" ref-type="bibr">20</xref>]. We still need more computational tools to produce low-cost, rapid predictions of NPS and to pave the way for the earlier identification of emerging drugs.</p>
    <p>In this study, we present AddictedChem, which is a scientific database of controlled substances. The database integrates multiple dimensions of data, allowing the analysis of controlled substances from the perspectives of molecules, targets, and functional enrichment, facilitating the discovery of new targets and drugs for the treatment and prevention of addictive diseases. We also created a consensus model to predict NPS to accelerate experimental NPS identification. Finally, we visually explored the chemical space of addictive compounds and discovered the spatial distribution patterns of NPS and controlled substances, providing the user with an interactive online exploration platform (<uri xlink:href="http://design.rxnfinder.org/addictedchem/chemical_space">http://design.rxnfinder.org/addictedchem/chemical_space</uri>). AddictedChem will facilitate further addictive compound research and identification.</p>
  </sec>
  <sec sec-type="results" id="sec2-molecules-27-03931">
    <title>2. Results and Discussion</title>
    <sec id="sec2dot1-molecules-27-03931">
      <title>2.1. Overview of AddictedChem</title>
      <p>The developed analysis platform comprises two parts (<xref rid="molecules-27-03931-f001" ref-type="fig">Figure 1</xref>): the knowledge base of 622 controlled substances (classified as shown in <xref rid="molecules-27-03931-f002" ref-type="fig">Figure 2</xref>A) and the NPS prediction platform. Five search methods, namely, text query, structure, similarity, maximum common substructure (MCS), and fragment, are available in the knowledge base.</p>
      <p>The user can directly enter the name or structure of a controlled substance to obtain the relevant literature, target, ADMET, gene, pathway, and bioassay information (<xref rid="molecules-27-03931-f002" ref-type="fig">Figure 2</xref>B). The text query method retrieves controlled substances using synonymous names from PubChem (see Materials and Methods for details).</p>
      <p>The structure search method requires the user to provide the compound in the simplified molecular input line entry specification (SMILES) format or use the JSME tool [<xref rid="B21-molecules-27-03931" ref-type="bibr">21</xref>] to draw the structure of the compound of interest. The JSME tool automatically converts the 2D molecular image into the SMILES format. The similarity retrieval method is based on a similarity algorithm [<xref rid="B22-molecules-27-03931" ref-type="bibr">22</xref>], which returns the 20 closest molecular structures of the compound searched in the AddictedChem database. The MCS retrieval method is based on the fMCS algorithm [<xref rid="B23-molecules-27-03931" ref-type="bibr">23</xref>] and returns 20 compounds with the largest substructure of the searched compound available in the AddictedChem database. Finally, the fragment retrieval method is based on the theory of connected subgraphs [<xref rid="B24-molecules-27-03931" ref-type="bibr">24</xref>]. After entering the chemical structure of a compound, all fragment structures of the compound are retrieved.</p>
      <p>In the NPS prediction platform, the user obtains the result report after entering the compound in the SMILES format or several compounds formatted in rows. The results are presented as three information sets: (1) consensus model results; (2) visualised results of 29 models based on seven descriptors, to be intuitively viewed by the user; and (3) specific prediction results of the 29 models in a list format. The website allows researchers to easily obtain prediction results.</p>
      <p>The addictive compounds are still far from saturation because more new psychoactive substances are emerging and have not been regulated completely. Because AddictedChem is an ongoing curation, it is continuously maintained and updated as new controlled substances are published. We will update the database annually to improve the comprehensiveness of data and collect more information about emerging controlled substances from more countries and regions in the future.</p>
    </sec>
    <sec id="sec2dot2-molecules-27-03931">
      <title>2.2. Scaffold Analysis of Controlled Substances</title>
      <p>The analysis of 622 controlled substances using Murcko scaffolds method yielded 245 scaffolds. <xref rid="molecules-27-03931-f002" ref-type="fig">Figure 2</xref>C shows the 10 most common scaffolds in controlled substances from different schedules. The top five scaffolds were benzene (11.09%), 1,3-dihydro-5-phenyl-1,4-benzodiazepin-2-one (3.54%), 4-phenylpiperidine (3.38%), 4-anilino-<italic toggle="yes">N</italic>-phenethyl-piperidine (3.38%), and acyclic (2.25%). The benzene ring is a common core scaffold in many chemical databases [<xref rid="B25-molecules-27-03931" ref-type="bibr">25</xref>]. 1,3-Dihydro-5-phenyl-1,4-benzodiazepin-2-one is found in flurazepam, lorazepam, and oxazepam; 4-phenylpiperidine is mainly found in betameprodine, betaprodine, and alphaprodine; and 4-anilino-<italic toggle="yes">N</italic>-phenethyl-piperidine is mainly found in fentanyl, ocfentanil, and isobutyryl fentanyl, and it is the direct precursor of fentanyl and certain fentanyl analogues (such as acetylfentanyl).</p>
      <p>We then used the Murcko scaffolds method to analyse controlled substances classed into different schedules (<xref rid="app1-molecules-27-03931" ref-type="app">Supplementary Figure S1</xref>). The analysis revealed that 1,3-dihydro-5-phenyl-1,4-benzodiazepin-2-one is mainly found in Schedule IV drugs, 4-phenylpiperidine is mainly found in Schedule I and II drugs, and 4-anilino-<italic toggle="yes">N</italic>-phenethyl-piperidine is mainly found in Schedule I drugs. Notably, the top three scaffolds of Schedule III drugs are the same isomer, indicating that the structures of the Schedule III drugs are the most similar. These findings showed the diversity of the scaffolds of controlled substances, but the scaffolds of controlled substances with the same schedule are similar.</p>
    </sec>
    <sec id="sec2dot3-molecules-27-03931">
      <title>2.3. Analysis of Controlled Substance Targets</title>
      <p>We then analysed controlled substance targets and used the PubChem ID of a compound of interest as the basis to search for its target information in the BindingDB database [<xref rid="B13-molecules-27-03931" ref-type="bibr">13</xref>]. Analysis revealed that as of 4 January 2021, only 144 controlled substances (of 622) were associated with 104 (after deduplication) target studies, which comprised 475 compound–target pairs (<xref rid="molecules-27-03931-f003" ref-type="fig">Figure 3</xref>).</p>
      <p>Considering the binding drug targets (<xref rid="molecules-27-03931-f002" ref-type="fig">Figure 2</xref>D), the most common target of the identified 144 compounds was the Mu-type opioid receptor (UniProt ID: P35372), targeted by 26 compounds; followed by the delta-type opioid receptor (UniProt ID: P41143), targeted by 25 compounds; and the Kappa-type opioid receptor (UniProt ID: P41145), targeted by 24 compounds. While these three targets all interact with Schedule I–IV drugs, they mostly interact with Schedule II drugs. The fourth most common target was the sodium-dependent serotonin transporter (targeted by 19 compounds), which mainly interacts with Schedule I drugs. The other common targets were canalicular multi-specific organic anion transporter 2 (targeted by 18 compounds) and multidrug resistance-associated protein 4 (also targeted by 18 compounds), which mainly interact with Schedule IV drugs. Based on drug classification and statistical analysis of controlled substances from different schedules (<xref rid="app1-molecules-27-03931" ref-type="app">Supplementary Tables S1–S5</xref>), Schedule II drugs had the highest degree of polymerisation, which was mainly because most of these compounds target cannabinoid receptors.</p>
      <p>Considering the compound type (<xref rid="molecules-27-03931-f002" ref-type="fig">Figure 2</xref>E), the controlled substances with the greatest number of targets were 3,4-methylenedioxymethamphetamine (MDMA), 25I-NBOMe, chlordiazepoxide, acetaminophen (APAP), and lacosamide. MDMA, as a Schedule I drug, induces the reversal of human serotonin transporters, leading to serotonin release [<xref rid="B26-molecules-27-03931" ref-type="bibr">26</xref>]. Another Schedule I drug, 25I-NBOMe, is a synthetic hallucinogen that is a derivative of the 2C-I family of substituted phenethylamines. The main receptor of 25I-NBOMe is the human 5-HT<sub>2A</sub> receptor, and the compound interacts weakly with other receptors. Chlordiazepoxide, a Schedule IV drug, is a sedative and hypnotic drug from the benzodiazepine class. It interacts with GABA<sub>A</sub> receptors/ion channels, influencing the central nervous system [<xref rid="B27-molecules-27-03931" ref-type="bibr">27</xref>]. APAP, a Schedule IV drug, is a common analgesic and antipyretic drug that acts on many targets. Finally, lacosamide, a Schedule V drug, is an anticonvulsant compound. Controlled substances always activate or inhibit key targets in the signal transduction of the central nervous system; hence, identifying these targets helps to discover the mechanism of addiction.</p>
    </sec>
    <sec id="sec2dot4-molecules-27-03931">
      <title>2.4. Functional Enrichment Analysis</title>
      <p>The analysis results revealed that pathway information was available for 166 controlled substances with 985 compound–pathway combinations. For the functional pathways of controlled substances, we observed that pathway information was available for 122 controlled substances with 209 compound–pathway combinations. Of the small number of the controlled substances (122), nearly 37% are related to the GABA-A receptor agonists/antagonists, which is followed by opioid receptor agonists/antagonists (<xref rid="molecules-27-03931-f002" ref-type="fig">Figure 2</xref>F). This is in line with the mechanism by which most regulated substances target receptor agonists or inhibitors.</p>
      <p>However, it is worth noting that because of data deficiency, the pathway analysis was conducted only on controlled substances that have reported targets and pathways and did not take dose effects into consideration.</p>
      <p>Likewise, we identified 261 compounds and 442 related genes in humans. We counted 5637 gene ontology (GO) annotations for these genes, of which 203 were significantly enriched, and we identified the top 40 GO annotations that were significantly enriched (<xref rid="app1-molecules-27-03931" ref-type="app">Supplementary Figure S2</xref>). GO analysis revealed that genes that interact with controlled substances were significantly enriched in the steroid metabolic process, response to the drug, response to oxidative process, and the metabolic process of fatty acids. Furthermore, biological process (BP) accounted for 90% of the 203 enriched GO annotations, indicating that addictive compounds are mainly involved in biological processes. These results reveal that controlled substances are widely involved in metabolic pathways in the human body and play a role in biological processes.</p>
    </sec>
    <sec id="sec2dot5-molecules-27-03931">
      <title>2.5. Model Performance for NPS Prediction</title>
      <p>Using seven types of molecular descriptors and five machine learning algorithms, we built 29 models to predict potential NPS. The model’s performance on external validation and test sets is summarised in <xref rid="molecules-27-03931-t001" ref-type="table">Table 1</xref>.</p>
      <p>As shown, most models performed well with the test and external validation sets. Model performance with the test set was better than that with the external validation set. Because the test set was extracted from and constituted 20% of the entire dataset, the external validation set was collated using external data for verification. Among the seven molecular feature description methods, Morgan fingerprint performed the best with the four traditional machine learning models with the test set. The performance of SECFP with the NB, RF, and SVM models with the validation set was better than with the test set.</p>
      <p>Meanwhile, the performance of the deep learning model was not better than traditional machine learning. The deep learning model performed well with the test set, but its performance with the external validation set was average. Among traditional machine learning models, the RF model performed the best, which was followed by SVM, LR, and NB. The best performance with the test set was obtained with the RF model based on MACCS (BA of 0.940 and AUC of 0.986) (<xref rid="molecules-27-03931-t001" ref-type="table">Table 1</xref>). The best performance with the external validation set was obtained with the NF model based on SECFP (BA of 0.919 and AUC of 0.968). However, as shown in <xref rid="molecules-27-03931-t001" ref-type="table">Table 1</xref>, some models including NB::Mol2vec, LR::RDkit, RF::MHFP6, and ChemBERT have extremely poor performance. We deduced that model overfitting might have caused some models to perform much worse on the external validation set than on the test set. The test set and the training set belong to the same source, although the compounds are different. Compared with the test set, the external validation set is a completely different source. Furthermore, the number of externally labelled validation sets is very small. These reasons may cause some overfitted models to perform poorly on external validation sets. Hence, we selected RF::MACCS and NB::SECFP from the 29 models to form a consensus model. For intuitive comparison, we further compared the receiver-operating characteristic (ROC) and PR curves of all these methods; in the machine learning algorithm, we used Morgan fingerprint because it was very stable in all models (<xref rid="molecules-27-03931-f004" ref-type="fig">Figure 4</xref>). The analysis revealed the necessity of constructing a consensus model that retained the best model performance and feature description to the greatest extent.</p>
      <p>The consensus scoring model is used for the online classification prediction function of addictive compounds. Deoxymethoxetamine (DXME) is a hallucinogen from the arylcyclohexylamine family that exerts dissociative effects. It has emerged on the illicit market since October 2020 and was first identified by a Danish forensic laboratory in February 2021 [<xref rid="B28-molecules-27-03931" ref-type="bibr">28</xref>]. As a newly included NPS by HighResNPS (<uri xlink:href="https://highresnps.forensic.ku.dk">https://highresnps.forensic.ku.dk</uri>, accessed on 27 April 2022), DXME does not appear in our datasets. We predicted DXME using the online prediction function freely available at <uri xlink:href="http://design.rxnfinder.org/addictedchem/prediction/">http://design.rxnfinder.org/addictedchem/prediction/</uri>. Our consensus model correctly predicted it as an addictive compound (<xref rid="app1-molecules-27-03931" ref-type="app">Supplementary Figure S3</xref>). This finding, to some extent, indicates that our model can predict potential NPS.</p>
      <p>Despite our best efforts to collect compound addiction datasets, the datasets collected in this study are still small. This may affect the model’s ability to discriminate structurally unique novel addictive compounds. In the future, we will try new machine learning algorithms to model methods, including positive unlabelled learning and few shot learning, to further expand the generalisation ability and robustness of the model.</p>
    </sec>
    <sec id="sec2dot6-molecules-27-03931">
      <title>2.6. Exploration of the Chemical Space of Addictive Compounds</title>
      <p>To show the chemical space of addictive compounds more intuitively, we created vectorisations of all the compounds used in the mathematical method and explored their spatial distribution patterns. The TMAP (tree-map) [<xref rid="B29-molecules-27-03931" ref-type="bibr">29</xref>] visualisation result (<xref rid="molecules-27-03931-f005" ref-type="fig">Figure 5</xref>) shows the two-dimensional distribution of molecules on the tree and reflects similarities calculated in the high-dimensional MHFP6 space. The compounds in schedules of controlled substances (red) and abused drugs listed by the Cayman Chemical Company (blue) were positive samples, and DrugBank (green) and Generally Recognised as Safe (GRAS) (purple) compounds were negative samples (<xref rid="molecules-27-03931-f005" ref-type="fig">Figure 5</xref>). The visualisation shows that the positive and negative classes clustered (<xref rid="molecules-27-03931-f005" ref-type="fig">Figure 5</xref>), and abused drugs from the Cayman Company list surrounded the compounds in schedules of controlled substances. On a local magnification scale, some addictive analogues surrounded the same controlled compound, such as the controlled substance methanone (inset, <xref rid="molecules-27-03931-f005" ref-type="fig">Figure 5</xref>). Its analogues undergo some simple changes, such as a single terminal bond becoming a double bond, a bond change, or the addition of F, Cl, or Br atoms. As shown in <xref rid="molecules-27-03931-f005" ref-type="fig">Figure 5</xref>, most areas of chemical space around controlled substances (red) remain unexplored, which means that there are still many possibilities for NPS to be designed. Thus, expanding the chemical space may accelerate potential NPS discovery research. The user can visit the interactive version to interactively experience the space of addictive compounds.</p>
    </sec>
  </sec>
  <sec id="sec3-molecules-27-03931">
    <title>3. Materials and Methods</title>
    <sec id="sec3dot1-molecules-27-03931">
      <title>3.1. Data Sources</title>
      <p>A detailed summary of all datasets used in this study is shown in <xref rid="app1-molecules-27-03931" ref-type="app">Supplementary Table S6</xref>. To construct a machine learning model for the classification of addictive compounds, we collected compound data from various publicly available sources. We carefully screened 854 data sources from PubChem [<xref rid="B30-molecules-27-03931" ref-type="bibr">30</xref>], which is the world’s largest collection of freely accessible chemical information to acquire many addiction-related compounds. Among them, substances controlled under the laws and regulations of the United States are listed by the DEA. It provides a relatively comprehensive list and is easily accessible. Furthermore, the Cayman Chemical Company is known as a provider of reference standards to crime labs. Therefore, the positive samples were finally derived from the list of controlled substances by the DEA and a list of abused drugs from Cayman Chemical Company. The compounds in the first list were divided into five schedules according to risk, abuse, and addiction. Schedules I–V contain 622 compounds, with 259 in Schedule I; 102 in Schedule II; 138 in Schedule III; 114 in Schedule IV; and 9 in Schedule V. The second list contains 1880 compounds. Because many of its components are NPS, these compounds were included as positive samples. Before the analysis, controlled substances were removed from that list. The negative samples, which contain compounds considered non-addictive, were also derived from two lists. The first is a list of GRAS compounds from the US Foods and Drug Administration. The compound names were converted to a SMILES [<xref rid="B31-molecules-27-03931" ref-type="bibr">31</xref>] format by using PubChemPy (<uri xlink:href="https://pubchempy.readthedocs.io/en/latest/">https://pubchempy.readthedocs.io/en/latest/</uri>, accessed on 31 December 2021), and the compounds without SMILES were deleted, yielding 173 compounds. The second list was from DrugBank [<xref rid="B11-molecules-27-03931" ref-type="bibr">11</xref>]. To avoid the problem of sample imbalance, the ratio of positive to negative samples was set to 1:1. Therefore, 2329 compounds were finally randomly selected from the second list after removing controlled substances, NPS, and GRAS compounds. The above datasets were used for model training and testing.</p>
      <p>The external validation sets for model evaluation are derived from two main sources (<xref rid="app1-molecules-27-03931" ref-type="app">Supplementary Table S6</xref>). The 2017–2020 NFLIS-Drug substance list [<xref rid="B32-molecules-27-03931" ref-type="bibr">32</xref>] provided by DEA constituted positive sample data for the external validation set and contained 184 substances. The NFLIS-Drug contains the results of drug chemistry analyses and associated information from drug cases. Negative samples for the external validation set were 149 newly approved drugs retrieved from the Kyoto Encyclopaedia of Genes and Genomes (KEGG) [<xref rid="B33-molecules-27-03931" ref-type="bibr">33</xref>] for the period 2017–2021.</p>
      <p>In addition to modelling-related data, there are more datasets for data analysis and database construction (<xref rid="app1-molecules-27-03931" ref-type="app">Supplementary Table S6</xref>). Basic physical and chemical attribute information and bioassay information for controlled substances were obtained from PubChem [<xref rid="B30-molecules-27-03931" ref-type="bibr">30</xref>], which was searched using a list of controlled substances obtained from the DEA. The literature on controlled substances was obtained from the literature section in PubChem, which was based on the individual compound interface. ADMET data were obtained from admetSAR [<xref rid="B12-molecules-27-03931" ref-type="bibr">12</xref>], which were divided into experimental and predicted data categories on chemicals. The data on controlled substance targets were obtained from BindingDB [<xref rid="B13-molecules-27-03931" ref-type="bibr">13</xref>]. Interactions between the controlled substances and pathways and GO annotations originate from CTD [<xref rid="B14-molecules-27-03931" ref-type="bibr">14</xref>]. The metabolic pathway data of controlled substances were acquired from the small-molecule pathway database (SMPDB) [<xref rid="B34-molecules-27-03931" ref-type="bibr">34</xref>], which is a great source of metabolic information for many psychoactive drugs.</p>
    </sec>
    <sec id="sec3dot2-molecules-27-03931">
      <title>3.2. Data Curation</title>
      <p>For subsequent modelling and database construction, we processed all compounds obtained from sources to maintain the quality of the final data. We used the open source cheminformatics toolkit RDKit [<xref rid="B35-molecules-27-03931" ref-type="bibr">35</xref>] (<uri xlink:href="http://www.rdkit.org">http://www.rdkit.org</uri>) to evaluate the SMILES of compounds for validity and to discard invalid molecules. We then normalised the effective compound structures using RDKit.</p>
    </sec>
    <sec id="sec3dot3-molecules-27-03931">
      <title>3.3. Data Analysis</title>
      <sec id="sec3dot3dot1-molecules-27-03931">
        <title>3.3.1. Scaffold Analysis of Controlled Substances</title>
        <p>Murcko scaffolds [<xref rid="B36-molecules-27-03931" ref-type="bibr">36</xref>] were used to analyse the molecular characteristics of the controlled substances and explore their diversity. The Murcko scaffolds calculation method involves retaining the ring structure of the compound and the linker between the ring structures and removing all the side chains on the ring structure. The Murcko scaffolds algorithm was implemented based on RDKit [<xref rid="B35-molecules-27-03931" ref-type="bibr">35</xref>], which is a chemical information toolkit.</p>
      </sec>
      <sec id="sec3dot3dot2-molecules-27-03931">
        <title>3.3.2. Target Analysis of Controlled Substances</title>
        <p>Cytoscape 3.7.0 [<xref rid="B37-molecules-27-03931" ref-type="bibr">37</xref>] was used to comprehensively evaluate the targets of controlled substances to analyse the relationship between controlled substances classified at different addiction levels and their targets. The controlled substance list was from the DEA. The control substance targets were from BindingDB [<xref rid="B13-molecules-27-03931" ref-type="bibr">13</xref>]. The relationship between controlled substances and their effects from the perspective of compounds and targets was statistically analysed using Python.</p>
      </sec>
      <sec id="sec3dot3dot3-molecules-27-03931">
        <title>3.3.3. Functional Enrichment Analysis</title>
        <p>To evaluate the functional genes targeted by controlled substances, pathway enrichment and GO annotation analyses were performed. The MeSH ID [<xref rid="B38-molecules-27-03931" ref-type="bibr">38</xref>] of the controlled substances was a standard to retrieve pathway information related to controlled substances from CTD [<xref rid="B14-molecules-27-03931" ref-type="bibr">14</xref>]. That is because the database already contains the information annotated from the literature on the relationship between manually annotated compounds and genes or proteins. There are two main parts in pathway analysis: one part is that, according to the manual annotated compound and gene data list in the CTD database, the R package clusterProfiler [<xref rid="B39-molecules-27-03931" ref-type="bibr">39</xref>] was employed to conduct KEGG pathway enrichment analysis using compound-associated genes, and we considered only the pathways with <italic toggle="yes">p</italic> values lower than 0.1. The other part is that because the first part can be enriched only from the first to sixth categories (1. Metabolism–6. Human Diseases) and does not contain key functional pathways (7. Drug Development), we used Python to retrieve the seventh category in the KEGG pathway for controlled substances. Because the seventh pathway designs the mechanism of addiction, we performed a functional summary of the seventh pathway data.</p>
        <p>The clusterProfiler package [<xref rid="B39-molecules-27-03931" ref-type="bibr">39</xref>] was used for GO annotation analysis of gene sets related to controlled substances.</p>
      </sec>
    </sec>
    <sec id="sec3dot4-molecules-27-03931">
      <title>3.4. Model Construction</title>
      <p>Seven molecular feature representation methods were used to characterise compounds of interest, including RDKit descriptors and E-state [<xref rid="B40-molecules-27-03931" ref-type="bibr">40</xref>], MACCS [<xref rid="B41-molecules-27-03931" ref-type="bibr">41</xref>], RDKit fingerprint, Morgan fingerprint [<xref rid="B42-molecules-27-03931" ref-type="bibr">42</xref>], SMILES-extended contiguity fingerprint (SECFP) [<xref rid="B43-molecules-27-03931" ref-type="bibr">43</xref>], MinHash fingerprint (MHFP6) [<xref rid="B43-molecules-27-03931" ref-type="bibr">43</xref>], and Mol2vec [<xref rid="B44-molecules-27-03931" ref-type="bibr">44</xref>] (data dimensions: 279, 166, 2048, 2048, 2048, 2048, and 300, respectively). The first six of these methods use RDKit, whereas Mol2vec uses an unsupervised machine learning method based on Python.</p>
      <p>Four machine learning methods, logistic regression (LR) [<xref rid="B45-molecules-27-03931" ref-type="bibr">45</xref>], naive Bayes (NB) [<xref rid="B46-molecules-27-03931" ref-type="bibr">46</xref>], random forest (RF) [<xref rid="B47-molecules-27-03931" ref-type="bibr">47</xref>], and support vector machine (SVM) [<xref rid="B48-molecules-27-03931" ref-type="bibr">48</xref>] were adopted, which were implemented based on scikit-learn [<xref rid="B49-molecules-27-03931" ref-type="bibr">49</xref>]. The training set and test set were randomly generated (ratio: 8:2). In addition, a deep learning method model, ChemBERTa_zinc250k_v2_40k from ChemBERTa [<xref rid="B50-molecules-27-03931" ref-type="bibr">50</xref>], was used for pre-training. It was then fine-tuned for 10 epochs using the generated dataset. The dataset was divided into a training set, a test set, and an internal validation set in a ratio of 8:1:1.</p>
      <p>After creating 29 models based on seven molecular feature representation methods and five machine learning algorithms, two models that performed the best with the external validation set and the test set were selected to create a consensus model for NPS prediction. To ascertain highly rigorous NPS prediction, the integrated model predicted a positive result when either of the two models yielded a positive result and a negative result when both models predicted a negative result.</p>
    </sec>
    <sec id="sec3dot5-molecules-27-03931">
      <title>3.5. Performance Evaluation</title>
      <p>In this study, test and external validation sets were used to evaluate the model performance based on the following parameters: true positive (<italic toggle="yes">TP</italic>), false negative (<italic toggle="yes">FN</italic>), true negative (<italic toggle="yes">TN</italic>), false positive (<italic toggle="yes">FP</italic>), sensitivity (<italic toggle="yes">SE</italic>), specificity (<italic toggle="yes">SP</italic>), balance accuracy (<italic toggle="yes">BA</italic>), and Matthew’s correlation coefficient (<italic toggle="yes">MCC</italic>), as defined below (Equations (1)–(7)).
<disp-formula id="FD1-molecules-27-03931"><label>(1)</label><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:mtext> </mml:mtext><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD2-molecules-27-03931"><label>(2)</label><mml:math id="mm2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>S</mml:mi><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:mtext> </mml:mtext><mml:mi>F</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD3-molecules-27-03931"><label>(3)</label><mml:math id="mm3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>B</mml:mi><mml:mi>A</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mo>×</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mi>E</mml:mi><mml:mo>+</mml:mo><mml:mi>S</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD4-molecules-27-03931"><label>(4)</label><mml:math id="mm4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>M</mml:mi><mml:mi>C</mml:mi><mml:mi>C</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mtext> </mml:mtext><mml:mo>×</mml:mo><mml:mtext> </mml:mtext><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mtext> </mml:mtext><mml:mo>−</mml:mo><mml:mtext> </mml:mtext><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mtext> </mml:mtext><mml:mo>×</mml:mo><mml:mtext> </mml:mtext><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:msqrt><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:mtext> </mml:mtext><mml:mi>F</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:mtext> </mml:mtext><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:mtext> </mml:mtext><mml:mi>F</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>T</mml:mi><mml:mi>N</mml:mi><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:mtext> </mml:mtext><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD5-molecules-27-03931"><label>(5)</label><mml:math id="mm5" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:mtext> </mml:mtext><mml:mi>F</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD6-molecules-27-03931"><label>(6)</label><mml:math id="mm6" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>R</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:mtext> </mml:mtext><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD7-molecules-27-03931"><label>(7)</label><mml:math id="mm7" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>F</mml:mi><mml:mn>1</mml:mn><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mtext> </mml:mtext><mml:mo>×</mml:mo><mml:mtext> </mml:mtext><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mtext> </mml:mtext><mml:mo>×</mml:mo><mml:mtext> </mml:mtext><mml:mi>R</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mtext> </mml:mtext><mml:mo>+</mml:mo><mml:mtext> </mml:mtext><mml:mi>R</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula></p>
      <p>The <italic toggle="yes">F</italic>1-measure (<italic toggle="yes">F</italic>1) score, ROC curve, and area under ROC (AUC) were also used to evaluate model performance.</p>
    </sec>
    <sec id="sec3dot6-molecules-27-03931">
      <title>3.6. Chemical Space Exploration</title>
      <p>To explore the chemical space of addictive compounds, we visualized the chemical space occupied by all molecules in the model building datasets using TMAP (tree-map) [<xref rid="B29-molecules-27-03931" ref-type="bibr">29</xref>], which is capable of representing large datasets and arbitrary high dimensionality as a two-dimensional tree. We considered the SMILES of all compounds as input and computed their MHFP6 molecular fingerprints [<xref rid="B43-molecules-27-03931" ref-type="bibr">43</xref>]. Then, LSH Forest [<xref rid="B51-molecules-27-03931" ref-type="bibr">51</xref>] was used to generate indexes for fast k-nearest neighbour [<xref rid="B52-molecules-27-03931" ref-type="bibr">52</xref>] retrieval. Furthermore, the data points indexed in the LSH forest were used to generate an undirected weighted graph of c-approximate k-nearest neighbour (c-k-NNG). We applied Kruskal’s algorithm to construct a minimum spanning tree on the weighted c-k-NNG. Finally, the Python package Faerun [<xref rid="B29-molecules-27-03931" ref-type="bibr">29</xref>] was used to visualise the data and show the resulting MST. The interactive version results are freely available at <uri xlink:href="http://design.rxnfinder.org/addictedchem/chemical_space">http://design.rxnfinder.org/addictedchem/chemical_space</uri>.</p>
    </sec>
    <sec id="sec3dot7-molecules-27-03931">
      <title>3.7. Database and Webserver</title>
      <p>The comprehensive addicted compounds portal comprises a front-end user interface and a back-end database. The data used in the construction of the database mainly include those of controlled substances from DEA, basic physical and chemical attributes, bioassays for controlled substances from PubChem and literature on controlled substances from PubChem [<xref rid="B30-molecules-27-03931" ref-type="bibr">30</xref>] and PubMed, experimental and predicted ADMET data from admetSAR [<xref rid="B12-molecules-27-03931" ref-type="bibr">12</xref>], enriched associations between controlled substances and pathways from CTD [<xref rid="B14-molecules-27-03931" ref-type="bibr">14</xref>], enriched associations between controlled substances and GO annotations from CTD [<xref rid="B14-molecules-27-03931" ref-type="bibr">14</xref>], and metabolic pathway data of controlled substances from the SMPDB [<xref rid="B34-molecules-27-03931" ref-type="bibr">34</xref>]. All of the above information is presented to the user through the search function module, which has five kinds of search methods. AddictedChem provides a browse function for all listed addictive compounds in our database. The user can either download the list of chemicals or follow the link to the compound details page. For the prediction of potential addictive compounds, we implemented an online prediction tool that uses a consensus scoring model formed with the RF::MACCS and NB::SECFP models. The entire project was implemented using Ubuntu (18.04.2), and the back-end framework used Django (2.2) based on Python (3.7.8). The data for the entire project are stored in MySQL (8.0.16). The ECharts (4.2.0) software was used as a graphical visualisation framework. The Bootstrap table (1.15.5) was used for static and dynamic data table display and relied on Bootstrap (3.3.7) and jQuery (2.1.1). Using the Chrome web browser is recommended to access and browse the database. AddictedChem is freely available to the research community at <uri xlink:href="http://design.rxnfinder.org/addictedchem/">http://design.rxnfinder.org/addictedchem/</uri>. The users do not have to register or login to access the features of the databases. User-friendly online tutorials are provided to facilitate user hands-on operations at <uri xlink:href="http://design.rxnfinder.org/addictedchem/help/">http://design.rxnfinder.org/addictedchem/help/</uri>. Finally, AddictedChem is an online platform outside the box, and the user can download all the data from <uri xlink:href="http://design.rxnfinder.org/addictedchem/downloads/">http://design.rxnfinder.org/addictedchem/downloads/</uri>.</p>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="sec4-molecules-27-03931">
    <title>4. Conclusions</title>
    <p>We constructed AddictedChem, a comprehensive database of controlled substances; analysed the existing data on molecular scaffolds, targets, gene-related pathways, and GO annotations; and developed a consistence predictive model based on multiple molecular description approaches and machine learning algorithms to assist NPS identification and analysis. Concurrently, we built a chemical space of addictive compounds, which revealed the chemical diversity of NPS. As the first step in the data-driven identification of potentially addictive molecules, this research can be applied to a wide range of scenarios, such as providing a preliminary assessment of drug addiction in the early stages of new drug development, identifying new addictive illegal drugs circulating on the market, and discovering potentially addictive components in food to improve food safety. In the next step, we will combine the prediction model with the metabolite identification model and untargeted metabolomic data to establish a more comprehensive analysis to better support the identification and detection of new illegal drugs. With these potential applications, we expect that AddictedChem will become an indispensable tool for use in future NPS studies.</p>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p><bold>Publisher’s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
  </fn-group>
  <app-group>
    <app id="app1-molecules-27-03931">
      <title>Supplementary Materials</title>
      <p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/molecules27123931/s1">https://www.mdpi.com/article/10.3390/molecules27123931/s1</uri>, Table S1: Targets of Schedule I drugs. Table S2: Targets of Schedule II drugs. Table S3: Targets of Schedule III drugs. Table S4: Targets of Schedule IV drugs. Table S5: Targets of Schedule V drugs. Table S6: Summary of all datasets. Figure S1: Top five scaffolds of controlled substances among different-schedule drugs. Figure S2: Gene Ontology (GO) functional annotation of interaction genes of controlled substances. Figure S3: Application of addictive compound prediction in AddictedChem.</p>
      <supplementary-material id="molecules-27-03931-s001" position="float" content-type="local-data">
        <media xlink:href="molecules-27-03931-s001.zip">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </app>
  </app-group>
  <notes>
    <title>Author Contributions</title>
    <p>Conceptualization, M.H. and S.L.; methodology, M.H.; software, S.L. and H.X.; validation, D.L., D.Z. and R.Z.; formal analysis, M.H.; investigation, S.L.; resources, M.H.; data curation, D.S. and L.G.; writing—original draft preparation, M.H. and S.L.; writing—review and editing, P.C.; visualisation, S.L.; supervision, Q.-N.H.; project administration, J.C. and W.T.; funding acquisition, Q.-N.H. All authors have read and agreed to the published version of the manuscript.</p>
  </notes>
  <notes>
    <title>Institutional Review Board Statement</title>
    <p>Not applicable.</p>
  </notes>
  <notes>
    <title>Informed Consent Statement</title>
    <p>Not applicable.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Data Availability Statement</title>
    <p>AddictedChem is freely accessible at <uri xlink:href="http://design.rxnfinder.org/addictedchem/">http://design.rxnfinder.org/addictedchem/</uri>. Classification models and relevant codes are available at <uri xlink:href="https://doi.org/10.5281/zenodo.6508755">https://doi.org/10.5281/zenodo.6508755</uri>. All the datasets in the project can be found at <uri xlink:href="http://design.rxnfinder.org/addictedchem/downloads">http://design.rxnfinder.org/addictedchem/downloads</uri>.</p>
  </notes>
  <notes notes-type="COI-statement">
    <title>Conflicts of Interest</title>
    <p>The authors declare no conflict of interest.</p>
  </notes>
  <ref-list>
    <title>References</title>
    <ref id="B1-molecules-27-03931">
      <label>1.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <collab>United Nations Office on Drugs and Crime</collab>
        </person-group>
        <source>World Drug Report 2021</source>
        <publisher-name>United Nations Office on Drugs and Crime</publisher-name>
        <publisher-loc>Vienna, Austria</publisher-loc>
        <year>2021</year>
      </element-citation>
    </ref>
    <ref id="B2-molecules-27-03931">
      <label>2.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <collab>United Nations</collab>
        </person-group>
        <source>Single Convention on Narcotic Drugs of 1961 as Amended by the 1972 Protocol Amending the Single Convention on Narcotic Drugs 1961</source>
        <publisher-name>United Nations</publisher-name>
        <publisher-loc>New York, NY, USA</publisher-loc>
        <year>1961</year>
      </element-citation>
    </ref>
    <ref id="B3-molecules-27-03931">
      <label>3.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <collab>United Nations</collab>
        </person-group>
        <source>Convention on Psychotropic Substances of 1971</source>
        <publisher-name>United Nations</publisher-name>
        <publisher-loc>New York, NY, USA</publisher-loc>
        <year>1971</year>
      </element-citation>
    </ref>
    <ref id="B4-molecules-27-03931">
      <label>4.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <collab>United Nations</collab>
        </person-group>
        <source>United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances</source>
        <publisher-name>United Nations</publisher-name>
        <publisher-loc>New York, NY, USA</publisher-loc>
        <year>1988</year>
      </element-citation>
    </ref>
    <ref id="B5-molecules-27-03931">
      <label>5.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <collab>Congressional Research Service</collab>
        </person-group>
        <source>The Controlled Substances Act (CSA):A Legal Overview for the 117th Congress</source>
        <publisher-name>Congressional Research Service</publisher-name>
        <publisher-loc>Washington, DC, USA</publisher-loc>
        <year>2021</year>
      </element-citation>
    </ref>
    <ref id="B6-molecules-27-03931">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Giannini</surname>
            <given-names>A.J.</given-names>
          </name>
        </person-group>
        <article-title>An approach to drug abuse, intoxication and withdrawal</article-title>
        <source>Am. Fam. Physician</source>
        <year>2000</year>
        <volume>61</volume>
        <fpage>2763</fpage>
        <lpage>2774</lpage>
        <?supplied-pmid 10821156?>
        <pub-id pub-id-type="pmid">10821156</pub-id>
      </element-citation>
    </ref>
    <ref id="B7-molecules-27-03931">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Arias-Carrión</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Stamelou</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Murillo-Rodríguez</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Menéndez-González</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Pöppel</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>Dopaminergic reward system: A short integrative review</article-title>
        <source>Int. Arch. Med.</source>
        <year>2010</year>
        <volume>3</volume>
        <fpage>24</fpage>
        <pub-id pub-id-type="doi">10.1186/1755-7682-3-24</pub-id>
        <?supplied-pmid 20925949?>
        <pub-id pub-id-type="pmid">20925949</pub-id>
      </element-citation>
    </ref>
    <ref id="B8-molecules-27-03931">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wise</surname>
            <given-names>R.A.</given-names>
          </name>
          <name>
            <surname>Rompre</surname>
            <given-names>P.P.</given-names>
          </name>
        </person-group>
        <article-title>Brain dopamine and reward</article-title>
        <source>Annu. Rev. Psychol.</source>
        <year>1989</year>
        <volume>40</volume>
        <fpage>191</fpage>
        <lpage>225</lpage>
        <pub-id pub-id-type="doi">10.1146/annurev.ps.40.020189.001203</pub-id>
        <?supplied-pmid 2648975?>
        <pub-id pub-id-type="pmid">2648975</pub-id>
      </element-citation>
    </ref>
    <ref id="B9-molecules-27-03931">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Johnson</surname>
            <given-names>S.W.</given-names>
          </name>
          <name>
            <surname>North</surname>
            <given-names>R.A.</given-names>
          </name>
        </person-group>
        <article-title>Opioids excite dopamine neurons by hyperpolarization of local interneurons</article-title>
        <source>J. Neurosci.</source>
        <year>1992</year>
        <volume>12</volume>
        <fpage>483</fpage>
        <lpage>488</lpage>
        <pub-id pub-id-type="doi">10.1523/JNEUROSCI.12-02-00483.1992</pub-id>
        <?supplied-pmid 1346804?>
        <pub-id pub-id-type="pmid">1346804</pub-id>
      </element-citation>
    </ref>
    <ref id="B10-molecules-27-03931">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lüscher</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Ungless</surname>
            <given-names>M.A.</given-names>
          </name>
        </person-group>
        <article-title>The mechanistic classification of addictive drugs</article-title>
        <source>PLoS Med.</source>
        <year>2006</year>
        <volume>3</volume>
        <elocation-id>e437</elocation-id>
        <pub-id pub-id-type="doi">10.1371/journal.pmed.0030437</pub-id>
        <pub-id pub-id-type="pmid">17105338</pub-id>
      </element-citation>
    </ref>
    <ref id="B11-molecules-27-03931">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wishart</surname>
            <given-names>D.S.</given-names>
          </name>
          <name>
            <surname>Feunang</surname>
            <given-names>Y.D.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>A.C.</given-names>
          </name>
          <name>
            <surname>Lo</surname>
            <given-names>E.J.</given-names>
          </name>
          <name>
            <surname>Marcu</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Grant</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Sajed</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Sayeeda</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DrugBank 5.0: A major update to the DrugBank database for 2018</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>D1074</fpage>
        <lpage>D1082</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id>
        <pub-id pub-id-type="pmid">29126136</pub-id>
      </element-citation>
    </ref>
    <ref id="B12-molecules-27-03931">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Lou</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>admetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties</article-title>
        <source>Bioinformatics</source>
        <year>2019</year>
        <volume>35</volume>
        <fpage>1067</fpage>
        <lpage>1069</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/bty707</pub-id>
        <pub-id pub-id-type="pmid">30165565</pub-id>
      </element-citation>
    </ref>
    <ref id="B13-molecules-27-03931">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gilson</surname>
            <given-names>M.K.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Baitaluk</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Nicola</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Hwang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Chong</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2016</year>
        <volume>44</volume>
        <fpage>D1045</fpage>
        <lpage>D1053</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkv1072</pub-id>
        <pub-id pub-id-type="pmid">26481362</pub-id>
      </element-citation>
    </ref>
    <ref id="B14-molecules-27-03931">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Davis</surname>
            <given-names>A.P.</given-names>
          </name>
          <name>
            <surname>Grondin</surname>
            <given-names>C.J.</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>R.J.</given-names>
          </name>
          <name>
            <surname>Sciaky</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Wiegers</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wiegers</surname>
            <given-names>T.C.</given-names>
          </name>
          <name>
            <surname>Mattingly</surname>
            <given-names>C.J.</given-names>
          </name>
        </person-group>
        <article-title>Comparative Toxicogenomics Database (CTD): Update 2021</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2021</year>
        <volume>49</volume>
        <fpage>D1138</fpage>
        <lpage>D1143</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkaa891</pub-id>
        <pub-id pub-id-type="pmid">33068428</pub-id>
      </element-citation>
    </ref>
    <ref id="B15-molecules-27-03931">
      <label>15.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <collab>European Monitoring Centre for Drugs and Drug Addiction</collab>
        </person-group>
        <source>European Drug Report 2021: Trends and Developments</source>
        <publisher-name>European Monitoring Centre for Drugs and Drug Addiction</publisher-name>
        <publisher-loc>Lisbon, Portugal</publisher-loc>
        <year>2021</year>
        <fpage>60</fpage>
      </element-citation>
    </ref>
    <ref id="B16-molecules-27-03931">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schifano</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Chiappini</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Corkery</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Guirguis</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review</article-title>
        <source>Brain Sci.</source>
        <year>2018</year>
        <volume>8</volume>
        <elocation-id>73</elocation-id>
        <pub-id pub-id-type="doi">10.3390/brainsci8040073</pub-id>
      </element-citation>
    </ref>
    <ref id="B17-molecules-27-03931">
      <label>17.</label>
      <element-citation publication-type="webpage">
        <person-group person-group-type="author">
          <collab>UNODC</collab>
        </person-group>
        <article-title>Early Warning Advisory on New Psychoactive Substances</article-title>
        <year>2022</year>
        <comment>Available online: <ext-link xlink:href="https://www.unodc.org/LSS/Page/NPS" ext-link-type="uri">https://www.unodc.org/LSS/Page/NPS</ext-link></comment>
        <date-in-citation content-type="access-date" iso-8601-date="2022-04-19">(accessed on 19 April 2022)</date-in-citation>
      </element-citation>
    </ref>
    <ref id="B18-molecules-27-03931">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Glennon</surname>
            <given-names>R.A.</given-names>
          </name>
        </person-group>
        <article-title>Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention</article-title>
        <source>Adv. Pharmacol.</source>
        <year>2014</year>
        <volume>69</volume>
        <fpage>581</fpage>
        <lpage>620</lpage>
        <?supplied-pmid 24484988?>
        <pub-id pub-id-type="pmid">24484988</pub-id>
      </element-citation>
    </ref>
    <ref id="B19-molecules-27-03931">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Peacock</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Bruno</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Gisev</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Degenhardt</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Hall</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Sedefov</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>White</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>K.V.</given-names>
          </name>
          <name>
            <surname>Farrell</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Griffiths</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>New psychoactive substances: Challenges for drug surveillance, control, and public health responses</article-title>
        <source>Lancet</source>
        <year>2019</year>
        <volume>394</volume>
        <fpage>1668</fpage>
        <lpage>1684</lpage>
        <pub-id pub-id-type="doi">10.1016/S0140-6736(19)32231-7</pub-id>
        <pub-id pub-id-type="pmid">31668410</pub-id>
      </element-citation>
    </ref>
    <ref id="B20-molecules-27-03931">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Melo</surname>
            <given-names>E.B.D.</given-names>
          </name>
          <name>
            <surname>Martins</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Rodrigues</surname>
            <given-names>C.H.</given-names>
          </name>
          <name>
            <surname>Bruni</surname>
            <given-names>A.T.</given-names>
          </name>
        </person-group>
        <article-title>In silico risk assessment studies of new psychoactive substances derived from amphetamines and cathinones</article-title>
        <source>J. Braz. Chem. Soc.</source>
        <year>2020</year>
        <volume>31</volume>
        <fpage>927</fpage>
        <lpage>940</lpage>
      </element-citation>
    </ref>
    <ref id="B21-molecules-27-03931">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bienfait</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Ertl</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>JSME: A free molecule editor in JavaScript</article-title>
        <source>J. Cheminformatics</source>
        <year>2013</year>
        <volume>5</volume>
        <fpage>24</fpage>
        <pub-id pub-id-type="doi">10.1186/1758-2946-5-24</pub-id>
      </element-citation>
    </ref>
    <ref id="B22-molecules-27-03931">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bajusz</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Rácz</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Héberger</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations?</article-title>
        <source>J. Cheminformatics</source>
        <year>2015</year>
        <volume>7</volume>
        <fpage>20</fpage>
        <pub-id pub-id-type="doi">10.1186/s13321-015-0069-3</pub-id>
        <?supplied-pmid 26052348?>
        <pub-id pub-id-type="pmid">26052348</pub-id>
      </element-citation>
    </ref>
    <ref id="B23-molecules-27-03931">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cao</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Girke</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>A maximum common substructure-based algorithm for searching and predicting drug-like compounds</article-title>
        <source>Bioinformatics</source>
        <year>2008</year>
        <volume>24</volume>
        <fpage>i366</fpage>
        <lpage>i374</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btn186</pub-id>
        <pub-id pub-id-type="pmid">18586736</pub-id>
      </element-citation>
    </ref>
    <ref id="B24-molecules-27-03931">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Barnard</surname>
            <given-names>J.M.</given-names>
          </name>
        </person-group>
        <article-title>Substructure searching methods: Old and new</article-title>
        <source>J. Chem. Inf. Comput. Sci.</source>
        <year>1993</year>
        <volume>33</volume>
        <fpage>532</fpage>
        <lpage>538</lpage>
        <pub-id pub-id-type="doi">10.1021/ci00014a001</pub-id>
      </element-citation>
    </ref>
    <ref id="B25-molecules-27-03931">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Velkoborsky</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Hoksza</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>Scaffold analysis of PubChem database as background for hierarchical scaffold-based visualization</article-title>
        <source>J. Cheminformatics</source>
        <year>2016</year>
        <volume>8</volume>
        <fpage>74</fpage>
        <pub-id pub-id-type="doi">10.1186/s13321-016-0186-7</pub-id>
      </element-citation>
    </ref>
    <ref id="B26-molecules-27-03931">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Oeri</surname>
            <given-names>H.E.</given-names>
          </name>
        </person-group>
        <article-title>Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy</article-title>
        <source>J. Psychopharmacol.</source>
        <year>2021</year>
        <volume>35</volume>
        <fpage>512</fpage>
        <lpage>536</lpage>
        <pub-id pub-id-type="doi">10.1177/0269881120920420</pub-id>
        <pub-id pub-id-type="pmid">32909493</pub-id>
      </element-citation>
    </ref>
    <ref id="B27-molecules-27-03931">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Skerritt</surname>
            <given-names>J.H.</given-names>
          </name>
          <name>
            <surname>Johnston</surname>
            <given-names>G.A.</given-names>
          </name>
        </person-group>
        <article-title>Enhancement of GABA binding by benzodiazepines and related anxiolytics</article-title>
        <source>Eur. J. Pharmacol.</source>
        <year>1983</year>
        <volume>89</volume>
        <fpage>193</fpage>
        <lpage>198</lpage>
        <pub-id pub-id-type="doi">10.1016/0014-2999(83)90494-6</pub-id>
        <pub-id pub-id-type="pmid">6135616</pub-id>
      </element-citation>
    </ref>
    <ref id="B28-molecules-27-03931">
      <label>28.</label>
      <element-citation publication-type="webpage">
        <article-title>Alert from NDEWS Web Monitoring Team: Increases in Reddit Discussions of DMXE October 2020–March 2021</article-title>
        <year>2021</year>
        <comment>Available online: <ext-link xlink:href="https://ndews.org/?wysija-page=1&amp;controller=email&amp;action=view&amp;email_id=125&amp;wysijap=subscriptions" ext-link-type="uri">https://ndews.org/?wysija-page=1&amp;controller=email&amp;action=view&amp;email_id=125&amp;wysijap=subscriptions</ext-link></comment>
        <date-in-citation content-type="access-date" iso-8601-date="2021-03-26">(accessed on 26 March 2021)</date-in-citation>
      </element-citation>
    </ref>
    <ref id="B29-molecules-27-03931">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Probst</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Reymond</surname>
            <given-names>J.L.</given-names>
          </name>
        </person-group>
        <article-title>Visualization of very large high-dimensional data sets as minimum spanning trees</article-title>
        <source>J. Cheminformatics</source>
        <year>2020</year>
        <volume>12</volume>
        <fpage>12</fpage>
        <pub-id pub-id-type="doi">10.1186/s13321-020-0416-x</pub-id>
        <?supplied-pmid 33431043?>
        <pub-id pub-id-type="pmid">33431043</pub-id>
      </element-citation>
    </ref>
    <ref id="B30-molecules-27-03931">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Thiessen</surname>
            <given-names>P.A.</given-names>
          </name>
          <name>
            <surname>Bolton</surname>
            <given-names>E.E.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Fu</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Gindulyte</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Shoemaker</surname>
            <given-names>B.A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PubChem Substance and Compound Databases</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2016</year>
        <volume>44</volume>
        <fpage>D1202</fpage>
        <lpage>D1213</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkv951</pub-id>
        <?supplied-pmid 26400175?>
        <pub-id pub-id-type="pmid">26400175</pub-id>
      </element-citation>
    </ref>
    <ref id="B31-molecules-27-03931">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dalby</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Nourse</surname>
            <given-names>J.G.</given-names>
          </name>
          <name>
            <surname>Hounshell</surname>
            <given-names>W.D.</given-names>
          </name>
          <name>
            <surname>Gushurst</surname>
            <given-names>A.K.</given-names>
          </name>
          <name>
            <surname>Grier</surname>
            <given-names>D.L.</given-names>
          </name>
          <name>
            <surname>Leland</surname>
            <given-names>B.A.</given-names>
          </name>
          <name>
            <surname>Laufer</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Description of several chemical structure file formats used by computer programs developed at Molecular Design Limited</article-title>
        <source>J. Chem. Inf. Comput. Sci.</source>
        <year>1992</year>
        <volume>32</volume>
        <fpage>244</fpage>
        <lpage>255</lpage>
        <pub-id pub-id-type="doi">10.1021/ci00007a012</pub-id>
      </element-citation>
    </ref>
    <ref id="B32-molecules-27-03931">
      <label>32.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <collab>U.S. Drug Enforcement Administration</collab>
        </person-group>
        <source>2017–2020 NFLIS-Drug Substance List</source>
        <comment>D.C.D.</comment>
        <publisher-name>U.S. Drug Enforcement Administration</publisher-name>
        <publisher-loc>Springfield, VA, USA</publisher-loc>
        <year>2021</year>
      </element-citation>
    </ref>
    <ref id="B33-molecules-27-03931">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kanehisa</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Furumichi</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Tanabe</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Sato</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Morishima</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>KEGG: New perspectives on genomes, pathways, diseases and drugs</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2017</year>
        <volume>45</volume>
        <fpage>D353</fpage>
        <lpage>D361</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkw1092</pub-id>
        <pub-id pub-id-type="pmid">27899662</pub-id>
      </element-citation>
    </ref>
    <ref id="B34-molecules-27-03931">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jewison</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Disfany</surname>
            <given-names>F.M.</given-names>
          </name>
          <name>
            <surname>Liang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Knox</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Maciejewski</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Poelzer</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Huynh</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Arndt</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>SMPDB 2.0: Big Improvements to the Small Molecule Pathway Database</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2014</year>
        <volume>42</volume>
        <fpage>D478</fpage>
        <lpage>D484</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkt1067</pub-id>
        <pub-id pub-id-type="pmid">24203708</pub-id>
      </element-citation>
    </ref>
    <ref id="B35-molecules-27-03931">
      <label>35.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Landrum</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <source>RDKit: Open-Source Cheminformatics</source>
        <publisher-name>Gregory Landrum</publisher-name>
        <publisher-loc>Zurich, Switzerland</publisher-loc>
        <year>2006</year>
      </element-citation>
    </ref>
    <ref id="B36-molecules-27-03931">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bemis</surname>
            <given-names>G.W.</given-names>
          </name>
          <name>
            <surname>Murcko</surname>
            <given-names>M.A.</given-names>
          </name>
        </person-group>
        <article-title>The properties of known drugs. 1. Molecular frameworks</article-title>
        <source>J. Med. Chem.</source>
        <year>1996</year>
        <volume>39</volume>
        <fpage>2887</fpage>
        <lpage>2893</lpage>
        <pub-id pub-id-type="doi">10.1021/jm9602928</pub-id>
        <pub-id pub-id-type="pmid">8709122</pub-id>
      </element-citation>
    </ref>
    <ref id="B37-molecules-27-03931">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shannon</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Markiel</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Ozier</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Baliga</surname>
            <given-names>N.S.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J.T.</given-names>
          </name>
          <name>
            <surname>Ramage</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Amin</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Schwikowski</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Ideker</surname>
            <given-names>T.</given-names>
          </name>
        </person-group>
        <article-title>Cytoscape: A software environment for integrated models of biomolecular interaction networks</article-title>
        <source>Genome Res.</source>
        <year>2003</year>
        <volume>13</volume>
        <fpage>2498</fpage>
        <lpage>2504</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id>
        <pub-id pub-id-type="pmid">14597658</pub-id>
      </element-citation>
    </ref>
    <ref id="B38-molecules-27-03931">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rogers</surname>
            <given-names>F.B.</given-names>
          </name>
        </person-group>
        <article-title>Medical subject headings</article-title>
        <source>Bull. Med. Libr. Assoc.</source>
        <year>1963</year>
        <volume>51</volume>
        <fpage>114</fpage>
        <lpage>116</lpage>
        <pub-id pub-id-type="pmid">13982385</pub-id>
      </element-citation>
    </ref>
    <ref id="B39-molecules-27-03931">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>L.G.</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>Q.Y.</given-names>
          </name>
        </person-group>
        <article-title>clusterProfiler: An R package for comparing biological themes among gene clusters</article-title>
        <source>Omics J. Integr. Biol.</source>
        <year>2012</year>
        <volume>16</volume>
        <fpage>284</fpage>
        <lpage>287</lpage>
        <pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id>
      </element-citation>
    </ref>
    <ref id="B40-molecules-27-03931">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kier</surname>
            <given-names>L.B.</given-names>
          </name>
          <name>
            <surname>Hall</surname>
            <given-names>L.H.</given-names>
          </name>
        </person-group>
        <article-title>An electrotopological-state index for atoms in molecules</article-title>
        <source>Pharm. Res.</source>
        <year>1990</year>
        <volume>7</volume>
        <fpage>801</fpage>
        <lpage>807</lpage>
        <pub-id pub-id-type="doi">10.1023/A:1015952613760</pub-id>
        <pub-id pub-id-type="pmid">2235877</pub-id>
      </element-citation>
    </ref>
    <ref id="B41-molecules-27-03931">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Durant</surname>
            <given-names>J.L.</given-names>
          </name>
          <name>
            <surname>Leland</surname>
            <given-names>B.A.</given-names>
          </name>
          <name>
            <surname>Henry</surname>
            <given-names>D.R.</given-names>
          </name>
          <name>
            <surname>Nourse</surname>
            <given-names>J.G.</given-names>
          </name>
        </person-group>
        <article-title>Reoptimization of MDL keys for use in drug discovery</article-title>
        <source>J. Chem. Inf. Comput. Sci.</source>
        <year>2002</year>
        <volume>42</volume>
        <fpage>1273</fpage>
        <lpage>1280</lpage>
        <pub-id pub-id-type="doi">10.1021/ci010132r</pub-id>
        <?supplied-pmid 12444722?>
        <pub-id pub-id-type="pmid">12444722</pub-id>
      </element-citation>
    </ref>
    <ref id="B42-molecules-27-03931">
      <label>42.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rogers</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Hahn</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Extended-connectivity fingerprints</article-title>
        <source>J. Chem. Inf. Model.</source>
        <year>2010</year>
        <volume>50</volume>
        <fpage>742</fpage>
        <lpage>754</lpage>
        <pub-id pub-id-type="doi">10.1021/ci100050t</pub-id>
        <?supplied-pmid 20426451?>
        <pub-id pub-id-type="pmid">20426451</pub-id>
      </element-citation>
    </ref>
    <ref id="B43-molecules-27-03931">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Probst</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Reymond</surname>
            <given-names>J.L.</given-names>
          </name>
        </person-group>
        <article-title>A probabilistic molecular fingerprint for big data settings</article-title>
        <source>J. Cheminformatics</source>
        <year>2018</year>
        <volume>10</volume>
        <fpage>66</fpage>
        <pub-id pub-id-type="doi">10.1186/s13321-018-0321-8</pub-id>
        <?supplied-pmid 30564943?>
        <pub-id pub-id-type="pmid">30564943</pub-id>
      </element-citation>
    </ref>
    <ref id="B44-molecules-27-03931">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jaeger</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Fulle</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Turk</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Mol2vec: Unsupervised machine learning approach with chemical intuition</article-title>
        <source>J. Chem. Inf. Model.</source>
        <year>2018</year>
        <volume>58</volume>
        <fpage>27</fpage>
        <lpage>35</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.jcim.7b00616</pub-id>
        <pub-id pub-id-type="pmid">29268609</pub-id>
      </element-citation>
    </ref>
    <ref id="B45-molecules-27-03931">
      <label>45.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Wright</surname>
            <given-names>R.E.</given-names>
          </name>
        </person-group>
        <article-title>Logistic regression</article-title>
        <source>Reading and Understanding Multivariate Statistics</source>
        <publisher-name>American Psychological Association</publisher-name>
        <publisher-loc>Washington, DC, USA</publisher-loc>
        <year>1995</year>
        <fpage>217</fpage>
        <lpage>244</lpage>
      </element-citation>
    </ref>
    <ref id="B46-molecules-27-03931">
      <label>46.</label>
      <element-citation publication-type="confproc">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>H.J.A.</given-names>
          </name>
        </person-group>
        <article-title>The optimality of naive Bayes</article-title>
        <source>Proceedings of the 17th International Florida Artificial Intelligence Research Society Conference</source>
        <conf-loc>Miami Beach, FL, USA</conf-loc>
        <conf-date>12–14 May 2004</conf-date>
        <fpage>562</fpage>
        <lpage>567</lpage>
      </element-citation>
    </ref>
    <ref id="B47-molecules-27-03931">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Breiman</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>Machine Learning</article-title>
        <source>Mach. Learn.</source>
        <year>2001</year>
        <volume>45</volume>
        <fpage>5</fpage>
        <lpage>32</lpage>
        <pub-id pub-id-type="doi">10.1023/A:1010933404324</pub-id>
      </element-citation>
    </ref>
    <ref id="B48-molecules-27-03931">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cortes</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Vapnik</surname>
            <given-names>V.</given-names>
          </name>
        </person-group>
        <article-title>Support-vector networks</article-title>
        <source>Mach. Learn.</source>
        <year>1995</year>
        <volume>20</volume>
        <fpage>273</fpage>
        <lpage>297</lpage>
        <pub-id pub-id-type="doi">10.1007/BF00994018</pub-id>
      </element-citation>
    </ref>
    <ref id="B49-molecules-27-03931">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pedregosa</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Varoquaux</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Gramfort</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Michel</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Thirion</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Grisel</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Blondel</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Prettenhofer</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Weiss</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Dubourg</surname>
            <given-names>V.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Scikit-Learn: Machine Learning in Python</article-title>
        <source>J. Mach. Learn. Res.</source>
        <year>2011</year>
        <volume>12</volume>
        <fpage>2825</fpage>
        <lpage>2830</lpage>
      </element-citation>
    </ref>
    <ref id="B50-molecules-27-03931">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chithrananda</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>ChemBERTa: Large-scale self-supervised pretraining for molecular property prediction</article-title>
        <source>arXiv</source>
        <year>2020</year>
        <pub-id pub-id-type="arxiv">2010.09885</pub-id>
      </element-citation>
    </ref>
    <ref id="B51-molecules-27-03931">
      <label>51.</label>
      <element-citation publication-type="confproc">
        <person-group person-group-type="author">
          <name>
            <surname>Bawa</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Condie</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Ganesan</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>LSH Forest: Self-Tuning indexes for similarity search</article-title>
        <source>Proceedings of the 14th International Conference on World Wide Web, WWW 2005</source>
        <conf-loc>Chiba, Japan</conf-loc>
        <conf-date>10–14 May 2005</conf-date>
        <fpage>651</fpage>
        <lpage>660</lpage>
      </element-citation>
    </ref>
    <ref id="B52-molecules-27-03931">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fix</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Hodges</surname>
            <given-names>J.L.</given-names>
          </name>
        </person-group>
        <article-title>Discriminatory analysis. Nonparametric discrimination: Consistency properties</article-title>
        <source>Int. Stat. Rev. Rev. Int. Stat.</source>
        <year>1989</year>
        <volume>57</volume>
        <fpage>238</fpage>
        <lpage>247</lpage>
        <pub-id pub-id-type="doi">10.2307/1403797</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
<floats-group>
  <fig position="float" id="molecules-27-03931-f001">
    <label>Figure 1</label>
    <caption>
      <p>Flow chart of AddictedChem. (<bold>Left</bold>), multilevel database of controlled substances. (<bold>Right</bold>), NPS prediction platform.</p>
    </caption>
    <graphic xlink:href="molecules-27-03931-g001" position="float"/>
  </fig>
  <fig position="float" id="molecules-27-03931-f002">
    <label>Figure 2</label>
    <caption>
      <p>Statistical analysis of entries in AddictedChem. (<bold>A</bold>) Classification of controlled substances. (<bold>B</bold>) Number of controlled substances on different schedules. (<bold>C</bold>) Top 10 scaffolds of controlled substances, namely, benzene (11.09%), 1,3-dihydro-5-phenyl-1,4-benzodiazepin-2-one (3.54%), 4-phenylpiperidine (3.38%), 4-anilino-<italic toggle="yes">N</italic>-phenethyl-piperidine (3.38%), and acyclic (2.25%), diphenylmethane (2.25%), barbituric acid (1.71%), unnamed compound (1.61%), 1,3-benzodioxole (1.45%), unnamed compound (1.45%). The numbers indicate the frequency of occurrence of the scaffolds, and the percentage values are the ratio of every scaffold to 622 scaffolds. (<bold>D</bold>) Binding protein target ranking according to the number of controlled substances in the BindingDB database. (<bold>E</bold>) Controlled substances ranking according to the number of binding protein targets in the BindingDB database. (<bold>F</bold>) Pathway analysis of controlled substances. These pathways are from KEGG drug development class, and the numbers indicate the number of controlled substances.</p>
    </caption>
    <graphic xlink:href="molecules-27-03931-g002" position="float"/>
  </fig>
  <fig position="float" id="molecules-27-03931-f003">
    <label>Figure 3</label>
    <caption>
      <p>Map of controlled substances and their interaction targets. Hexagons represent controlled substances and circles are controlled substances. The hexagon and ellipse sizes represent the degree of connectivity. The circles formed by the shapes represent different levels of controlled substances and their targets. The circles arranged on a grid in the middle are targets that interact with multiple types of compounds. The number of compound targets gradually decreases, counter clockwise from the lowest point on the circle, as shown in the figure. Purple hexagons, Schedule I drugs; red hexagons, Schedule II drugs; orange hexagons, Schedule III drugs; yellow hexagons, Schedule IV drugs; green hexagons, Schedule V drugs. The figure was generated using Cytoscape (3.7.0).</p>
    </caption>
    <graphic xlink:href="molecules-27-03931-g003" position="float"/>
  </fig>
  <fig position="float" id="molecules-27-03931-f004">
    <label>Figure 4</label>
    <caption>
      <p>ROC curves and PR curves for models generated in the current study. (<bold>A</bold>) ROC curves for the test set. (<bold>B</bold>) ROC curves for the external validation set. (<bold>C</bold>) PR curves for the test set. (<bold>D</bold>) PR curves for the external validation set.</p>
    </caption>
    <graphic xlink:href="molecules-27-03931-g004" position="float"/>
  </fig>
  <fig position="float" id="molecules-27-03931-f005">
    <label>Figure 5</label>
    <caption>
      <p>TMAP visualisation of model building datasets in the MHFP6 chemical space. The MHFP6 molecular fingerprints were used to characterise the compounds, generate indexes for fast k-nearest neighbour retrieval using LSH Forest, and visualise data using Faerun. Each data point in the figure indicates a chemical compound. The links connecting the data points represent the edges of the minimum spanning tree. All chemical compounds are shown in colour according to the dataset source. GRAS compounds (purple), DEA controlled substances (red), Cayman Chemical Company abused drugs (blue), and DrugBank compounds (green). In the upper left corner is seen a partial enlargement of methanone and the surrounding compounds. Please use the interactive version at <uri xlink:href="http://design.rxnfinder.org/addictedchem/chemical_space">http://design.rxnfinder.org/addictedchem/chemical_space</uri> to visualise the molecular structures associated with each point.</p>
    </caption>
    <graphic xlink:href="molecules-27-03931-g005" position="float"/>
  </fig>
  <table-wrap position="float" id="molecules-27-03931-t001">
    <object-id pub-id-type="pii">molecules-27-03931-t001_Table 1</object-id>
    <label>Table 1</label>
    <caption>
      <p>Model performance with an external validation set and a test set.</p>
    </caption>
    <table frame="hsides" rules="groups">
      <thead>
        <tr>
          <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
          <th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
</th>
          <th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Test Set</th>
          <th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">External Validation Set</th>
        </tr>
        <tr>
          <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th>
          <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th>
          <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BA</th>
          <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCC</th>
          <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F1</th>
          <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUC</th>
          <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BA</th>
          <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCC</th>
          <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F1</th>
          <th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUC</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
            <bold>NB</bold>
          </td>
          <td align="center" valign="middle" rowspan="1" colspan="1">RDKit Descriptors+E-state</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.810</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.627</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.817</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.897</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.780</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.572</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.820</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.858</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">MACCS</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.794</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.595</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.803</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.887</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.806</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.629</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.844</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.895</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">RDKit fingerprint</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.794</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.588</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.786</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.865</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.844</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.687</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.835</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.920</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">Morgan fingerprint</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.909</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.818</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.905</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.969</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.911</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.817</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.912</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.961</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">SECFP</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.886</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.772</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.882</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.960</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.919</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.834</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.921</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.968</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">MHFP6</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.787</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.586</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.800</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.893</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.844</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.685</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.856</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.894</td>
        </tr>
        <tr>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mol2vec</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.714</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.472</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.754</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.779</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.606</td>
        </tr>
        <tr>
          <td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
            <bold>LR</bold>
          </td>
          <td align="center" valign="middle" rowspan="1" colspan="1">RDKit Descriptors+E-state</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.899</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.797</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.897</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.966</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.656</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.310</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.670</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.727</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">MACCS</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.894</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.787</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.891</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.962</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.741</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.480</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.760</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.837</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">RDKit fingerprint</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.919</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.838</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.917</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.967</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.903</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.805</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.913</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.964</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">Morgan fingerprint</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.931</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.862</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.929</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.974</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.837</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.683</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.864</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.898</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">SECFP</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.921</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.842</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.919</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.969</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.888</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.775</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.899</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.931</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">MHFP6</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.896</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.793</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.895</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.948</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.919</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.834</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.921</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.964</td>
        </tr>
        <tr>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mol2vec</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.894</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.787</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.892</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.959</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.774</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.544</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.784</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.848</td>
        </tr>
        <tr>
          <td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
            <bold>RF</bold>
          </td>
          <td align="center" valign="middle" rowspan="1" colspan="1">RDKit Descriptors+E-state</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.944</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.888</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.942</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.985</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.815</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.640</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.847</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.887</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">MACCS</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.940</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.880</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.938</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.986</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.892</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.786</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.906</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.950</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">RDKit fingerprint</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.942</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.887</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.940</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.973</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.951</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.898</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.953</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.965</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">Morgan fingerprint</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.950</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.900</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.948</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.983</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.921</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.842</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.929</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.960</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">SECFP</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.942</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.884</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.940</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.979</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.943</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.885</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.948</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.964</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">MHFP6</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.927</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.854</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.924</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.974</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.491</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">−0.019</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.574</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.500</td>
        </tr>
        <tr>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mol2vec</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.921</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.842</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.918</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.973</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.702</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.478</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.795</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.871</td>
        </tr>
        <tr>
          <td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
            <bold>SVM</bold>
          </td>
          <td align="center" valign="middle" rowspan="1" colspan="1">RDKit Descriptors+E-state</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.919</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.838</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.916</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.975</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.806</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.629</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.844</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.858</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">MACCS</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.921</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.842</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.918</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.980</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.860</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.720</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.875</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.927</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">RDKit fingerprint</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.942</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.884</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.939</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.975</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.930</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.856</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.933</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.959</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">Morgan fingerprint</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.933</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.870</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.929</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.978</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.928</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.854</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.934</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.956</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">SECFP</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.934</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.871</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.931</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.977</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.939</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.874</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.942</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.960</td>
        </tr>
        <tr>
          <td align="center" valign="middle" rowspan="1" colspan="1">MHFP6</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.890</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.780</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.889</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.955</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.747</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.546</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.664</td>
          <td align="center" valign="middle" rowspan="1" colspan="1">0.949</td>
        </tr>
        <tr>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mol2vec</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.907</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.814</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.906</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.971</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.799</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.629</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.847</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.910</td>
        </tr>
        <tr>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
            <bold>ChemBERTa</bold>
          </td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.934</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.868</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.935</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.979</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.629</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.256</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.644</td>
          <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.675</td>
        </tr>
      </tbody>
    </table>
    <table-wrap-foot>
      <fn>
        <p>MHFP6, MinHash fingerprint; NB, naive Bayes; RF, random forest; SECFP, SMILES-extended contiguity fingerprint; SVM, support vector machine.</p>
      </fn>
    </table-wrap-foot>
  </table-wrap>
</floats-group>
